JP2009503097A5 - - Google Patents

Download PDF

Info

Publication number
JP2009503097A5
JP2009503097A5 JP2008525163A JP2008525163A JP2009503097A5 JP 2009503097 A5 JP2009503097 A5 JP 2009503097A5 JP 2008525163 A JP2008525163 A JP 2008525163A JP 2008525163 A JP2008525163 A JP 2008525163A JP 2009503097 A5 JP2009503097 A5 JP 2009503097A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disease
prednisolone acetate
prednisolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008525163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009503097A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/030140 external-priority patent/WO2007019184A2/en
Publication of JP2009503097A publication Critical patent/JP2009503097A/ja
Publication of JP2009503097A5 publication Critical patent/JP2009503097A5/ja
Pending legal-status Critical Current

Links

JP2008525163A 2005-08-04 2006-08-03 酢酸プレドニゾロンの経口懸濁液 Pending JP2009503097A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70537005P 2005-08-04 2005-08-04
PCT/US2006/030140 WO2007019184A2 (en) 2005-08-04 2006-08-03 Oral suspension of prednisolone acetate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012236009A Division JP2013014634A (ja) 2005-08-04 2012-10-25 酢酸プレドニゾロンの経口懸濁液

Publications (2)

Publication Number Publication Date
JP2009503097A JP2009503097A (ja) 2009-01-29
JP2009503097A5 true JP2009503097A5 (https=) 2009-09-17

Family

ID=37727875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008525163A Pending JP2009503097A (ja) 2005-08-04 2006-08-03 酢酸プレドニゾロンの経口懸濁液
JP2012236009A Abandoned JP2013014634A (ja) 2005-08-04 2012-10-25 酢酸プレドニゾロンの経口懸濁液

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012236009A Abandoned JP2013014634A (ja) 2005-08-04 2012-10-25 酢酸プレドニゾロンの経口懸濁液

Country Status (11)

Country Link
US (4) US7799331B2 (https=)
EP (2) EP1909798A4 (https=)
JP (2) JP2009503097A (https=)
KR (1) KR20080044245A (https=)
CN (1) CN101247786A (https=)
AU (1) AU2006278620B2 (https=)
CA (1) CA2616112A1 (https=)
IL (1) IL189257A0 (https=)
NZ (1) NZ566117A (https=)
WO (1) WO2007019184A2 (https=)
ZA (1) ZA200800926B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799331B2 (en) 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007117605A2 (en) * 2006-04-06 2007-10-18 Taro Pharmaceuticals North America, Inc. Novel spill-resistant formulations comprising hydrocolloidal polymers
CN101888829A (zh) * 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
US20090149433A1 (en) 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
HUE051538T2 (hu) * 2008-08-20 2021-03-01 Univ California Kortikoszteroidok a gyomor-bél traktus gyulladásos betegségeinek kezelésére
WO2010144865A2 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CA3023243C (en) * 2016-05-06 2020-01-21 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions and methods for fabricating thereof
EP3509572A4 (en) * 2016-09-08 2020-05-13 Synergistic Therapeutics, LLC TOPICAL FORMULATION FOR HAIR GROWTH

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265823A (en) * 1979-01-04 1981-05-05 Robert E. Kosinski Aurothiosteroids
US4448774A (en) * 1982-12-22 1984-05-15 Fisons Corporation Steroid formulation
US5145675A (en) * 1986-03-31 1992-09-08 Advanced Polymer Systems, Inc. Two step method for preparation of controlled release formulations
EP0653209A4 (en) * 1992-07-30 1997-03-19 Tokyo Tanabe Co Remedy for inflammatory intestinal diseases.
IL108366A (en) * 1993-03-11 1999-11-30 Taro Vit Ind Ltd Semi-solid pharmaceutical compounds and a device for their use
US5881926A (en) * 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5480914A (en) 1994-05-06 1996-01-02 Allergan, Inc. Nonaqueous thixotropic drug delivery suspensions and methods of their use
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
AU2002240115B2 (en) * 2001-01-24 2007-01-04 Discus Dental, Llc. Topical oral care compositions
NZ532310A (en) 2001-10-05 2007-02-23 Combinatorx Inc Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
CA2469616A1 (en) 2001-12-12 2003-06-19 James W. Aiken Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
CA2486553C (en) 2002-06-17 2012-01-10 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
DE602004008083T2 (de) * 2003-06-19 2008-04-24 Nicholas S. Gainsville Bodor Verstärkung der aktivität und/oder wirkdauer von ausgewählten entzündungshemmenden steroiden
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
JP2007533697A (ja) * 2004-04-22 2007-11-22 デュオコート エービー グルココルチコイド救急治療用の医薬組成物
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
US7799331B2 (en) 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate

Similar Documents

Publication Publication Date Title
ES2742525T3 (es) Composiciones de corticosteroides administradas oralmente
JP2009503097A5 (https=)
ES2339790T3 (es) Efecto neuroprotector de udca solubilizado en modelo isquemico focal.
ES2658166T3 (es) Producto para administración oral
US8840924B2 (en) Compositions and methods of making rapidly dissolving ionically masked formulations
ES2462536T3 (es) Comprimido orodispersable multicapa
JP5841151B2 (ja) 鼻腔噴霧剤
ES3027652T3 (en) Orally inhaled and nasal benzodiazepines
KR20150011807A (ko) 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
ES2624585T3 (es) Sistema de suministro de compuesto terapéutico oral
TWI343263B (en) Patches for mucosa of oral cavity containing fentanyl
Behra et al. An exhaustive review on recent advancement in pharmaceutical bioadhesive used for systemic drug delivery through oral mucosa for achieving maximum pharmacological response and effect
EP4076380B1 (en) Transmucosal therapeutic system containing agomelatine
ES2744495T3 (es) Preparación farmacéutica sólida
ES2266288T3 (es) Pulverizador nasal tixotropico.
EP4076381B1 (en) Transmucosal therapeutic system containing agomelatine
ES2272689T3 (es) Dihidro-triterpenos en el tratamiento de infecciones virales, enfermedad cardiovascular, inflamacion, hipersensibilidad o dolor.
JP2005518435A5 (https=)
Patel et al. Mucoadhesive buccal drug delivery system.
EP3704123A1 (en) Hydrophobic acid addition salts and pharmaceutical formulations thereof
JP5828007B2 (ja) 局所投与型の嚥下障害改善用医薬品
ES2507570T3 (es) Terapia de combinación de Zn/trimetoprim
WO2011064769A1 (en) Methods and pharmaceutical compositions for the treatment of hot flashes
ES2746951T3 (es) Suspensión oral para tratar esofagitis eosinofílica
CN101842318A (zh) 用于治疗和预防呼吸疾病或病症的甘油磷酸钙